Evidence map›Paper›PMID 38975680›Full record

ReviewPediatric hematology and oncology2024

Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review.

Jane Koo, Jeffrey Hord, Craig Gilliam, Mary Lynn Rae, Katherine Staubach, Katherine Nowacki, Anne Lyren, Maitreya Coffey, Christopher E Dandoy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric hematology and oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jane KooDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Medical Center, Cincinnati, OH, USA.ORCID 0000-0003-1858-2881
Jeffrey HordShowers Family Center for Childhood Cancer and Blood Disorders, Akron Children's Hospital, Akron, OH, USA.
Craig GilliamDepartment of Infection Prevention and Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Mary Lynn RaeAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Katherine StaubachJames M Anderson Center for Health Systems Excellence, Cincinnati Children's Medical Center, Cincinnati, OH, USA.
Katherine NowackiJames M Anderson Center for Health Systems Excellence, Cincinnati Children's Medical Center, Cincinnati, OH, USA.
Anne LyrenCase Western Reserve University Cleveland, University Hospital Rainbow Babies & Children's Hospital Cleveland, Cleveland, OH, USA.
Maitreya CoffeyThe Hospital for Sick Children, Toronto, Ontario, USA.
Christopher E DandoyDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Medical Center, Cincinnati, OH, USA.

Funding

Reduction of bloodstream infections from oral organisms in pediatric stem cell transplant: a randomized multicenter double-blind placebo-controlled study evaluating twice daily oral xylitolUH3DE030401 · NIDCR · CINCINNATI CHILDRENS HOSP MED CTR · PI DANDOY, CHRISTOPHER EUGENE · 2022 to 2025
$2.1M
Reduction of bloodstream infections from oral organisms in pediatric stem cell transplant: a randomized, multicenter, double-blind, placebo-controlled study evaluating twice daily oral xylitolUG3DE030401 · NIDCR · CINCINNATI CHILDRENS HOSP MED CTR · PI DANDOY, CHRISTOPHER EUGENE · 2021 to 2021
$490k
NIDCR NIH HHS L40 DE029975NIDCR NIH HHS UG3 DE030401NIDCR NIH HHS UH3 DE030401
6 · The paper itself

Abstract

Bloodstream infections (BSI) are one of the leading causes of morbidity and mortality in children and young adults receiving chemotherapy for malignancy or undergoing hematopoietic stem cell transplantation (HSCT). Antibiotic prophylaxis is commonly used to decrease the risk of BSI; however, antibiotics carry an inherent risk of complications. The aim of this manuscript is to review levofloxacin prophylaxis in pediatric oncology patients and HSCT recipients. We reviewed published literature on levofloxacin prophylaxis to prevent BSI in pediatric oncology patients and HSCT recipients. Nine manuscripts were identified. The use of levofloxacin is indicated in neutropenic children and young adults receiving intensive chemotherapy for leukemia or undergoing HSCT. These results support the efficacy of levofloxacin in pediatric patients with leukemia receiving intensive chemotherapy and should be considered in pediatric patients undergoing HSCT prior to engraftment.

Indexed as

Hematopoietic Stem Cell TransplantationLevofloxacinAdolescentAdultAnti-Bacterial AgentsAntibiotic ProphylaxisChildChild, PreschoolFemaleHumansLeukemiaMaleNeoplasmsYoung AdultAnti-Bacterial AgentsLevofloxacinBlood stream infectionlevofloxacinpediatric bone marrow transplantpediatric cancerprophylaxis

Identifiers

PMID38975680
PMCPMC11335452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.